{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:39:31Z","timestamp":1768905571700,"version":"3.49.0"},"update-to":[{"DOI":"10.1016\/j.jaad.2018.01.028","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000}}],"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T00:00:00Z","timestamp":1516924800000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jaad.2018.01.028","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T10:19:19Z","timestamp":1517480359000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials"],"prefix":"10.1016","author":[{"given":"Linda","family":"Stein-Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon H.","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe Diane","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Werschler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joely","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil A.","family":"Tanghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Alvandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurpreet","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.01.028_bib1","first-page":"725","article-title":"Diagnosis and treatment of rosacea: state of the art","volume":"11","author":"Baldwin","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.01.028_bib2","series-title":"Rosacea now estimated to affect at least 16 million Americans. Rosacea Review","author":"Drake","year":"2010"},{"key":"10.1016\/j.jaad.2018.01.028_bib3","first-page":"26","article-title":"Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2018.01.028_bib4","series-title":"Rhofade [package insert]","year":"2017"},{"key":"10.1016\/j.jaad.2018.01.028_bib5","series-title":"Mirvaso [package insert]","year":"2016"},{"key":"10.1016\/j.jaad.2018.01.028_bib6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archderm.143.11.1369","article-title":"Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline","volume":"143","author":"Shanler","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.01.028_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40257-015-0156-2","article-title":"New and emerging treatments for rosacea","volume":"16","author":"Gold","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.01.028_bib8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2014.05.044","article-title":"Reliability of Clinician Erythema Assessment grading scale","volume":"71","author":"Tan","year":"2014","journal-title":"J Am Acad Dermatol"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2018.04.011","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"record-id":"18004"},{"DOI":"10.1016\/j.jaad.2018.04.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000}},{"DOI":"10.1016\/j.jaad.2018.01.028","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218301476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218301476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:01:28Z","timestamp":1759237288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218301476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":8,"alternative-id":["S0190962218301476"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.01.028","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Dermatology, Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}